Sagentia, an international technology and product development company, announced today it has been hired by T2 Biosystems to work on the development of T2 Biosystems’ next generation of medical diagnostic products to improve medical care worldwide.
“Sagentia’s commitment to T2 Biosystems directly reflects our mission to help our clients identify, adapt and deliver innovative technologies”
T2 Biosystems’ proprietary technology combines nanotechnology and the miniaturization of proven MR technology to develop rapid, accurate and portable diagnostics. T2 Biosystems’ underlying technology has been validated in multiple published journal articles and has shown to accurately analyze viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. Diagnostics systems are typically restricted to the use of optics or the electrical signals that can be derived from an assay, whereas T2 Biosystems’s technology uses magnetic resonance to quickly detect the presence of the assay’s target substances in extremely low concentrations. The magnetic interrogation of the sample does not require the degree of sample processing that existing optical technologies require, enabling a class of diagnostic testing not possible before for both molecular and immunodiagnostics that are faster, less expensive and more reliable.
The program will see Sagentia working with T2 Biosystems towards the complete development of its benchtop instrument for clinical trials and commercial release. Sagentia, which recently announced the concentration and expansion of its U.S. presence by opening a new office at One Broadway in Cambridge, Massachusetts, was chosen as the development partner due to its track record in running agile development projects that aim to bring new technologies and breakthrough products to market within short timescales. This includes complex diagnostic systems, which help change the competition for its clients, from earlier stage innovators like T2 Biosystems to global leaders across medical, consumer and industrial sectors.
“Sagentia’s commitment to T2 Biosystems directly reflects our mission to help our clients identify, adapt and deliver innovative technologies,” said Brent Hudson, Chief Executive Officer of Sagentia. “We are excited to work with T2 Biosystems in developing this novel diagnostic platform technology that will offer improved speed, accuracy and efficiency as well as portability to a broader range of settings including doctor’s offices, homes and hospitals. This project also clearly reflects the wider trend we are seeing towards growth in the point of care diagnostics market.”
“I’m very pleased to be working with Sagentia on this important initiative,” said John McDonough, Chief Executive Officer of T2 Biosystems. “We are focused on revolutionizing diagnostics. Sagentia’s depth of diagnostics expertise, strategic insight and understanding of industry trends, and multi-disciplinary approach will help us design the right product for the marketplace.”
Headquartered in Cambridge, U.K., Sagentia is a technology and product development company providing outsourced R&D consultancy services to start ups through to global market leaders in the medical, industrial and consumer sectors. Sagentia works with clients from front end need analysis through to transfer to manufacture delivering innovation and commercial value. It develops new technologies, products and services that change the basis of competition. The company also assists business leaders to create strategies for technology, innovation and growth. Sagentia’s resources are situated in state-of-the-art facilities in Europe, the U.S., and China. Information about Sagentia and its services can be found at www.sagentia.com.
About T2 Biosystems
T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts. For more information, please visit the company’s website at www.t2biosystems.com.